1445 related articles for article (PubMed ID: 8751593)
1. Cytokine production and antitumor effect of a nonreplicating, noncytopathic recombinant vaccinia virus expressing interleukin-12.
Meko JB; Tsung K; Norton JA
Surgery; 1996 Aug; 120(2):274-82; discussion 282-3. PubMed ID: 8751593
[TBL] [Abstract][Full Text] [Related]
2. High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12.
Meko JB; Yim JH; Tsung K; Norton JA
Cancer Res; 1995 Nov; 55(21):4765-70. PubMed ID: 7585501
[TBL] [Abstract][Full Text] [Related]
3. Low-dose vaccinia virus-mediated cytokine gene therapy of glioma.
Chen B; Timiryasova TM; Haghighat P; Andres ML; Kajioka EH; Dutta-Roy R; Gridley DS; Fodor I
J Immunother; 2001; 24(1):46-57. PubMed ID: 11211148
[TBL] [Abstract][Full Text] [Related]
4. Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1 beta.
Peplinski GR; Tsung K; Whitman ED; Meko JB; Norton JA
Ann Surg Oncol; 1995 Mar; 2(2):151-9. PubMed ID: 7728569
[TBL] [Abstract][Full Text] [Related]
5. Prevention of murine breast cancer by vaccination with tumor cells modified by cytokine-producing recombinant vaccinia viruses.
Peplinski GR; Tsung K; Meko JB; Norton JA
Ann Surg Oncol; 1996 Jan; 3(1):15-23. PubMed ID: 8770297
[TBL] [Abstract][Full Text] [Related]
6. Expression of secreted platelet-derived growth factor-B by recombinant nonreplicating and noncytopathic vaccina virus.
Norton A; Peplinski GR; Tsung K
Ann Surg; 1996 Oct; 224(4):555-60; discussion 560-2. PubMed ID: 8857859
[TBL] [Abstract][Full Text] [Related]
7. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12.
Gambotto A; Tüting T; McVey DL; Kovesdi I; Tahara H; Lotze MT; Robbins PD
Cancer Gene Ther; 1999; 6(1):45-53. PubMed ID: 10078963
[TBL] [Abstract][Full Text] [Related]
8. In vivo murine tumor gene delivery and expression by systemic recombinant vaccinia virus encoding interleukin-1beta.
Peplinski GR; Tsung AK; Casey MJ; Meko JB; Fredrickson TN; Buller RM; Norton JA
Cancer J Sci Am; 1996; 2(1):21-7. PubMed ID: 9166494
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy.
Whitman ED; Tsung K; Paxson J; Norton JA
Surgery; 1994 Aug; 116(2):183-8. PubMed ID: 8047984
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of combined vaccinia virus-mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model.
Chen B; Timiryasova TM; Andres ML; Kajioka EH; Dutta-Roy R; Gridley DS; Fodor I
Cancer Gene Ther; 2000 Nov; 7(11):1437-47. PubMed ID: 11129286
[TBL] [Abstract][Full Text] [Related]
11. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
[TBL] [Abstract][Full Text] [Related]
12. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant.
Puhlmann M; Brown CK; Gnant M; Huang J; Libutti SK; Alexander HR; Bartlett DL
Cancer Gene Ther; 2000 Jan; 7(1):66-73. PubMed ID: 10678358
[TBL] [Abstract][Full Text] [Related]
13. Cytokine-armed vaccinia virus infects the mesothelioma tumor microenvironment to overcome immune tolerance and mediate tumor resolution.
Jackaman C; Nelson DJ
Cancer Gene Ther; 2010 Jun; 17(6):429-40. PubMed ID: 20150930
[TBL] [Abstract][Full Text] [Related]
14. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.
Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O
Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752
[TBL] [Abstract][Full Text] [Related]
15. In vivo gene therapy of a murine pancreas tumor with recombinant vaccinia virus encoding human interleukin-1 beta.
Peplinski GR; Tsung K; Meko JB; Norton JA
Surgery; 1995 Aug; 118(2):185-90; discussion 190-1. PubMed ID: 7638732
[TBL] [Abstract][Full Text] [Related]
16. Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen.
Carroll MW; Overwijk WW; Surman DR; Tsung K; Moss B; Restifo NP
J Natl Cancer Inst; 1998 Dec; 90(24):1881-7. PubMed ID: 9862625
[TBL] [Abstract][Full Text] [Related]
17. Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity.
Kaufman HL; Flanagan K; Lee CS; Perretta DJ; Horig H
Vaccine; 2002 Mar; 20(13-14):1862-9. PubMed ID: 11906776
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines.
Akiyama Y; Watanabe M; Maruyama K; Ruscetti FW; Wiltrout RH; Yamaguchi K
Gene Ther; 2000 Dec; 7(24):2113-21. PubMed ID: 11223993
[TBL] [Abstract][Full Text] [Related]
19. Replication-deficient vaccinia virus gene therpay vector: evaluation of exogenous gene expression mediated by PUV-inactivated virus in glioma cells.
Timiryasova TM; Chen B; Fodor I
J Gene Med; 2001; 3(5):468-77. PubMed ID: 11601760
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses.
Griffith TS; Kawakita M; Tian J; Ritchey J; Tartaglia J; Sehgal I; Thompson TC; Zhao W; Ratliff TL
J Natl Cancer Inst; 2001 Jul; 93(13):998-1007. PubMed ID: 11438565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
